Sanguine technologies

Using proven patent-pending nanotechnology in new ways to pretreat patient samples, Sanguine Technologies develops novel diagnostic solutions to address currently unmet clinical needs and improve the accuracy of laboratory results, as well as the quality of patient care. As 80% of Sepsis deaths can be saved by early detection, every hour of treatment is important, and any delays in treatment increase the chance of tissue damage, organ failure, and death. To address this current health issue and market opportunity, Sanguine is developing revolutionary point of care technologies capable of detecting the specific cause of Sepsis and other biomarkers at very low costs within minutes.

Investment: $515,000

Health Care, Technology, Medical Devices, B2B